Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis
Tina Raselli(University of Zurich), Benjamin Misselwitz(University of Zurich), Philipp Schreiner(Medical University of Vienna), William J. Griffiths(Swansea University), Isabelle Frey‐Wagner(University of Zurich), Andreas Geier(Swiss Integrative Center for Human Health), Anja Moncsek(University Hospital of Zurich), Gerhard Rogler(University Hospital of Zurich), Andreas W. Sailer(Novartis (Switzerland)), Michael Scharl(Swiss Integrative Center for Human Health), Marianne R. Spalinger(University of Zurich), A. Misha Peter(University of Zurich), Marco Bueter(Doctors Hospital of Laredo), Kirstin Atrott(University of Zurich), Johannes Schmitt(Universitätsklinikum Würzburg), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Ewerton Marques Maggio(University of Zurich), Tom Hearn(Swansea University), Annika Wyss(University of Zurich), Yuqin Wang(Kunming Medical University)
Cited by 49
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Extraintestinal Manifestations of Inflammatory Bowel Disease
|Inflammatory Bowel Diseases|2015|891